Q3 Earnings Estimate for CeriBell Issued By William Blair

CeriBell (NASDAQ:CBLL) – Equities researchers at William Blair issued their Q3 2024 earnings per share (EPS) estimates for shares of CeriBell in a research report issued to clients and investors on Tuesday, November 5th. William Blair analyst M. Andrew forecasts that the company will post earnings of ($0.25) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for CeriBell’s Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.02) EPS and FY2026 earnings at ($0.91) EPS.

A number of other research analysts have also issued reports on CBLL. TD Cowen began coverage on shares of CeriBell in a report on Tuesday. They issued a “buy” rating and a $31.00 price objective for the company. Canaccord Genuity Group assumed coverage on shares of CeriBell in a research note on Tuesday. They issued a “buy” rating and a $30.00 price objective for the company. Canaccord Genuity Group assumed coverage on shares of CeriBell in a research report on Tuesday. They issued a “buy” rating and a $30.00 price target for the company. Bank of America assumed coverage on shares of CeriBell in a research report on Tuesday. They issued a “buy” rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a report on Tuesday. They set an “overweight” rating and a $32.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $31.00.

CeriBell Price Performance

CBLL opened at $28.95 on Thursday. CeriBell has a 1-year low of $23.00 and a 1-year high of $29.53.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.